142 related articles for article (PubMed ID: 22204903)
1. Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.
Cueva JP; Chemel BR; Juncosa JI; Lill MA; Watts VJ; Nichols DE
Eur J Med Chem; 2012 Feb; 48():97-107. PubMed ID: 22204903
[TBL] [Abstract][Full Text] [Related]
2. Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine.
Negash K; Nichols DE; Watts VJ; Mailman RB
J Med Chem; 1997 Jul; 40(14):2140-7. PubMed ID: 9216832
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands.
Brewster WK; Nichols DE; Watts VJ; Riggs RM; Mottola D; Mailman RB
J Med Chem; 1995 Jan; 38(2):318-27. PubMed ID: 7830274
[TBL] [Abstract][Full Text] [Related]
4. trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.
Cueva JP; Giorgioni G; Grubbs RA; Chemel BR; Watts VJ; Nichols DE
J Med Chem; 2006 Nov; 49(23):6848-57. PubMed ID: 17154515
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.
Knoerzer TA; Watts VJ; Nichols DE; Mailman RB
J Med Chem; 1995 Aug; 38(16):3062-70. PubMed ID: 7636869
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands.
Qandil AM; Lewis MM; Jassen A; Leonard SK; Mailman RB; Nichols DE
Bioorg Med Chem; 2003 Apr; 11(7):1451-64. PubMed ID: 12628671
[TBL] [Abstract][Full Text] [Related]
7. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.
Ghosh D; Snyder SE; Watts VJ; Mailman RB; Nichols DE
J Med Chem; 1996 Jan; 39(2):549-55. PubMed ID: 8558526
[TBL] [Abstract][Full Text] [Related]
8. Binding and preliminary evaluation of 5-hydroxy- and 10-hydroxy-2,3, 12,12a-tetrahydro-1H-[1]benzoxepino[2,3,4-ij]isoquinolines as dopamine receptor ligands.
Claudi F; Di Stefano A; Napolitani F; Cingolani GM; Giorgioni G; Fontenla JA; Montenegro GY; Rivas ME; Rosa E; Michelotto B; Orlando G; Brunetti L
J Med Chem; 2000 Feb; 43(4):599-608. PubMed ID: 10691686
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.
Przybyla JA; Cueva JP; Chemel BR; Hsu KJ; Riese DJ; McCorvy JD; Chester JA; Nichols DE; Watts VJ
Eur Neuropsychopharmacol; 2009 Feb; 19(2):138-46. PubMed ID: 19028082
[TBL] [Abstract][Full Text] [Related]
10. Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists.
Bonner LA; Chemel BR; Watts VJ; Nichols DE
Bioorg Med Chem; 2010 Sep; 18(18):6763-70. PubMed ID: 20709559
[TBL] [Abstract][Full Text] [Related]
11. Investigation of D₁ receptor-agonist interactions and D₁/D₂ agonist selectivity using a combination of pharmacophore and receptor homology modeling.
Malo M; Brive L; Luthman K; Svensson P
ChemMedChem; 2012 Mar; 7(3):483-94, 338. PubMed ID: 22315216
[TBL] [Abstract][Full Text] [Related]
12. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.
Mottola DM; Laiter S; Watts VJ; Tropsha A; Wyrick SD; Nichols DE; Mailman RB
J Med Chem; 1996 Jan; 39(1):285-96. PubMed ID: 8568818
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D1 receptor ligands: where are we now and where are we going.
Zhang J; Xiong B; Zhen X; Zhang A
Med Res Rev; 2009 Mar; 29(2):272-94. PubMed ID: 18642350
[TBL] [Abstract][Full Text] [Related]
14. 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms.
Grubbs RA; Lewis MM; Owens-Vance C; Gay EA; Jassen AK; Mailman RB; Nichols DE
Bioorg Med Chem; 2004 Mar; 12(6):1403-12. PubMed ID: 15018913
[TBL] [Abstract][Full Text] [Related]
15. trans-2,6-,3,6- and 4,6-diaza-5,6,6a,7,8,12b-hexahydro-benzo[c]phenanthrene-10,11- diols as dopamine agonists.
Gu YG; Bayburt EK; Michaelides MR; Lin CW; Shiosaki K
Bioorg Med Chem Lett; 1999 May; 9(10):1341-6. PubMed ID: 10360732
[TBL] [Abstract][Full Text] [Related]
16. Effects of dopamine D1 receptor full agonists in rats trained to discriminate SKF 38393.
Gleason SD; Witkin JM
Behav Pharmacol; 2004 Feb; 15(1):85-9. PubMed ID: 15075630
[TBL] [Abstract][Full Text] [Related]
17. Dihydrexidine--the first full dopamine D1 receptor agonist.
Salmi P; Isacson R; Kull B
CNS Drug Rev; 2004; 10(3):230-42. PubMed ID: 15492773
[TBL] [Abstract][Full Text] [Related]
18. Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.
Cueva JP; Gallardo-Godoy A; Juncosa JI; Vidi PA; Lill MA; Watts VJ; Nichols DE
J Med Chem; 2011 Aug; 54(15):5508-21. PubMed ID: 21714510
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists.
Minor DL; Wyrick SD; Charifson PS; Watts VJ; Nichols DE; Mailman RB
J Med Chem; 1994 Dec; 37(25):4317-28. PubMed ID: 7996543
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane.
Doll MK; Nichols DE; Kilts JD; Prioleau C; Lawler CP; Lewis MM; Mailman RB
J Med Chem; 1999 Mar; 42(5):935-40. PubMed ID: 10072690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
